PMID- 32445033
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 2038-3312 (Electronic)
IS  - 2038-131X (Linking)
VI  - 72
IP  - 3
DP  - 2020 Sep
TI  - Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma 
      different from that of hepatocellular carcinoma and mass-forming 
      cholangiocarcinoma? A case-matched analysis.
PG  - 671-679
LID - 10.1007/s13304-020-00802-w [doi]
AB  - Hepatocholangiocarcinoma (HCC-CC) is a rare malignancy containing features of 
      both hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC), 
      of which the outcome after hepatectomy remains to be clarified. The aim of this 
      study was to analyze the characteristics and outcomes of patients with 
      transitional HCC-CC and compare them with those of patients with HCC and MFCCC. 
      Our prospectively maintained database was queried, and 14 transitional HCC-CC 
      patients were identified over a total of 406 consecutive hepatic resections. A 
      1:1:1 match was performed with HCC and MFCCC patients operated in the same 
      period. A total of 42 patients were matched according to tumor stage (T1-2-3, N0, 
      M0), number of tumors, R0 resection, no 90-day mortality, and follow-up. Primary 
      endpoints were disease-free survival (DFS) and overall survival (OS). 
      Disease-free survival rates at 1-, 3-, and 5-year were 71.4%, 57.1%, 35.7% for 
      transitional HCC-CC patients; 85.7%, 40.4%, 10.1% for HCC patients; 85.1%, 34.0%, 
      22.7% for MFCCC patients (5-year DFS: HCC-CC vs. HCC, p = 0.575; HCC-CC vs. 
      MFCCC, p = 0.766, respectively). Similarly, OS rates at 1-, 3-, and 5-year were 
      92.9%, 71.4%, 64.3% for transitional HCC-CC patients; 100%, 64.3%, 41.7% for HCC 
      patients; 100%, 54.5%, 43.6% for MFCCC patients (5-year OS: HCC-CC vs. HCC, 
      p = 0.891; HCC-CC vs. MFCCC, p = 0.673, respectively). When accurately matched 
      with respect to tumor burden, transitional HCC-CC patients show similar outcomes 
      to those of HCC and MFCCC patients. Further evaluations of differences in tumor 
      biology are necessary to better characterize the prognosis of transitional HCC-CC 
      patients.
FAU - Gentile, Damiano
AU  - Gentile D
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy.
FAU - Donadon, Matteo
AU  - Donadon M
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy.
AD  - Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
FAU - Di Tommaso, Luca
AU  - Di Tommaso L
AD  - Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
AD  - Department of Pathology, Humanitas Clinical and Research Center-IRCCS, Rozzano, 
      Milan, Italy.
FAU - Sama, Laura
AU  - Sama L
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy.
FAU - Franchi, Eloisa
AU  - Franchi E
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy.
FAU - Costa, Guido
AU  - Costa G
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy.
FAU - Lleo, Ana
AU  - Lleo A
AD  - Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
AD  - Department of Internal Medicine, Humanitas Clinical and Research Center-IRCCS, 
      Rozzano, Milan, Italy.
FAU - Torzilli, Guido
AU  - Torzilli G
AUID- ORCID: 0000-0001-5798-5021
AD  - Department of Hepatobiliary and General Surgery, Humanitas Clinical and Research 
      Center-IRCCS, Rozzano, Milan, Italy. guido.torzilli@hunimed.eu.
AD  - Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, 
      Italy. guido.torzilli@hunimed.eu.
AD  - Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas 
      University, Humanitas Clinical and Research Center-IRCCS, Via Manzoni, 56, 20089, 
      Rozzano, Milano, Italy. guido.torzilli@hunimed.eu.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200522
PL  - Italy
TA  - Updates Surg
JT  - Updates in surgery
JID - 101539818
SB  - IM
MH  - Aged
MH  - Carcinoma, Hepatocellular/mortality/*surgery
MH  - Cholangiocarcinoma/mortality/*surgery
MH  - Female
MH  - *Hepatectomy
MH  - Humans
MH  - Liver Neoplasms/mortality/*surgery
MH  - Male
MH  - Middle Aged
MH  - *Neoplasms, Multiple Primary
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cholangiocarcinoma
OT  - Hepatectomy
OT  - Hepatocellular carcinoma
OT  - Hepatocholangiocarcinoma
OT  - Liver neoplasms
EDAT- 2020/05/24 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1007/s13304-020-00802-w [pii]
AID - 10.1007/s13304-020-00802-w [doi]
PST - ppublish
SO  - Updates Surg. 2020 Sep;72(3):671-679. doi: 10.1007/s13304-020-00802-w. Epub 2020 
      May 22.